Eurofins Scientific Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Eurofins Scientific de 20.3% y 7.5% por año respectivamente. Se prevé que el BPA crezca en un 19.2% al año. Se espera que la rentabilidad financiera sea de 12.6% en 3 años.

Información clave

20.4%

Tasa de crecimiento de los beneficios

19.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	21.7%
Tasa de crecimiento de los ingresos	7.4%
Rentabilidad financiera futura	12.3%
Cobertura de analistas	Good
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

WBAG:ESF - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	8,168	615	802	1,562	10
12/31/2025	7,590	557	723	1,372	13
12/31/2024	7,052	397	561	1,192	14
12/31/2023	6,515	257	468	1,018	N/A
9/30/2023	6,512	335	403	995	N/A
6/30/2023	6,510	414	339	971	N/A
3/31/2023	6,611	497	407	1,054	N/A
12/31/2022	6,712	581	476	1,136	N/A
9/30/2022	6,785	612	602	1,219	N/A
6/30/2022	6,857	643	727	1,301	N/A
3/31/2022	6,787	696	866	1,406	N/A
12/31/2021	6,718	749	1,005	1,511	N/A
9/30/2021	6,553	786	1,023	1,499	N/A
6/30/2021	6,388	824	1,041	1,487	N/A
3/31/2021	5,913	665	955	1,355	N/A
12/31/2020	5,439	505	868	1,224	N/A
9/30/2020	5,079	347	713	1,057	N/A
6/30/2020	4,719	190	558	891	N/A
3/31/2020	4,641	168	457	784	N/A
12/31/2019	4,563	146	355	678	N/A
9/30/2019	4,384	144	300	618	N/A
6/30/2019	4,205	143	244	558	N/A
3/31/2019	3,993	159	212	551	N/A
12/31/2018	3,781	175	180	544	N/A
9/30/2018	3,549	182	179	521	N/A
6/30/2018	3,318	190	178	498	N/A
3/31/2018	3,145	185	169	451	N/A
12/31/2017	2,971	179	159	405	N/A
9/30/2017	2,848	166	N/A	387	N/A
6/30/2017	2,725	152	N/A	369	N/A
3/31/2017	2,631	145	N/A	370	N/A
12/31/2016	2,537	138	N/A	372	N/A
9/30/2016	2,427	104	N/A	350	N/A
6/30/2016	2,317	69	N/A	328	N/A
3/31/2016	2,133	63	N/A	310	N/A
12/31/2015	1,950	56	N/A	291	N/A
9/30/2015	1,779	71	N/A	274	N/A
6/30/2015	1,609	86	N/A	256	N/A
3/31/2015	1,509	82	N/A	234	N/A
12/31/2014	1,410	78	N/A	212	N/A
9/30/2014	1,355	66	N/A	187	N/A
6/30/2014	1,299	53	N/A	162	N/A
3/31/2014	1,262	53	N/A	166	N/A
12/31/2013	1,226	53	N/A	169	N/A
9/30/2013	1,180	61	N/A	159	N/A
6/30/2013	1,134	69	N/A	148	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (20.3% al año) de ESF es superior a la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (20.3% al año) de ESF crezcan más rápidamente que el mercado Austrian (3% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de ESF crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (7.5% al año) de ESF crezcan más rápidamente que los del mercado Austrian (-2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.5% al año) de ESF crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ESF sea baja dentro de 3 años (12.6%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Eurofins Scientific Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Recent updates

Eurofins Scientific SE (ENXTPA:ERF) acquired Ascend Clinical, LLC.

Eurofins Scientific SE, Annual General Meeting, Apr 25, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €1.61 (vs €3.02 in FY 2022)

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €0.79 (vs €1.52 in 1H 2022)

Eurofins Scientific SE Updates Revenue Guidance for Fiscal Year 2023 and year 2027

Upcoming dividend of €1.00 per share at 1.8% yield

Now 22% undervalued after recent price drop

Eurofins Scientific SE to Report First Half, 2023 Results on Jul 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: €3.16 (vs €3.91 in FY 2021)

Now 20% undervalued after recent price drop

Eurofins Scientific SE to Report Fiscal Year 2022 Results on Feb 21, 2023

Eurofins Scientific SE to Report Q3, 2022 Results on Oct 18, 2022

Now 22% undervalued after recent price drop

Eurofins Scientific SE (ENXTPA:ERF) signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Eurofins Scientific SE (ENXTPA:ERF) acquired Wessling Hungary Kornyezetvedelmi, Elelmiszerbiztonsagi, Egeszsegvedelmi Es Minosegugyi Sz.

First half 2022 earnings released: EPS: €1.62 (vs €2.09 in 1H 2021)

Eurofins Scientific SE Revised Earnings Guidance for the Fiscal 2022

Upcoming dividend of €1.00 per share

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire unknown majority stake in Ajal for Laboratories from Saudi Ajal Laboratories.

Eurofins Scientific SE (ENXTPA:ERF) acquires an unknown majority stake in Repertoire Genesis Inc.

Health Canada Approves Eurofins CDMO Alphora Inc.’s Standard Processing License for Synthetic Phytocannabinoids

Eurofins Scientific SE Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Eurofins Scientific SE to Report Q1, 2022 Results on Apr 21, 2022

Eurofins’ empowerDX Launches PFAS Exposure™ in the U.S, the First at-Home Blood Test to Detect and Measure 40+ PFAS Compounds

Eurofins Technologies Launches New Lateral Flow Reader Rapidscan ST5-W as Single Platform Validated for Multiple Food and Environmental Rapid Tests

Eurofins Scientific SE (ENXTPA:ERF) entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342).

Eurofins Technologies Launches New Multiplex RT-PCR Respiratory Panel for SARS-CoV-2, Flu A, Flu B, RSV A and RSV B

First half 2021 earnings released: EPS €2.17 (vs €0.43 in 1H 2020)

Eurofins Scientific SE (ENXTPA:ERF) acquired bioskin GmbH.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 India Sars-Cov-2 Variant

Eurofins Scientific Adds Virus Variant Detection to its SARS-CoV-2 Monitoring Solution for Wastewater, Surface, Air and Worn Masks

Full year 2020 earnings released: EPS €2.71 (vs €0.82 in FY 2019)

Revenue beats expectations

Eurofins Environment Testing America Expands Reporting to 75 Compounds

Eurofins Scientific SE to Report Fiscal Year 2020 Results on Mar 01, 2021

Eurofins Scientific SE (ENXTPA:ERF) agreed to acquire Beacon Discovery, Inc.

Eurofins Adds Virus Variant Distinction to its Sars-Cov-2 Monitoring Solution for Wastewater, Food and Environmental Surfaces

Eurofins Launches New Ultra-Fast Extraction-Free RT-PCR Method and Upgrades its RT-PCR Assay for Use with Pharynx Gargle and Saliva Sample Matrices

New 90-day high: €80.51

New 90-day high: €73.16

Eurofins Genomics Launches Cost-Effective SARS-CoV-2 Full-Length Viral Genome Sequencing Services Essential in the Identification of Viral Mutations

Eurofins U.S. Clinical Diagnostic Laboratories At-Home COVID-19 Test Now Being Offered in All 50 States

Eurofins Technologies Launches New and Improved Lateral Flow Device Product Line for Allergen Detection in Foodstuffs and Environmental Samples

Eurofins Scientific SE (ENXTPA:ERF) acquired Taiyo Techno Research.

Eurofins Launches Sensitive, Fast and Cost-effective High Throughput SARS-CoV-2 Test Kits for Widely Available Sanger Sequencing Equipment

Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test

Eurofins Scientific Se Launches Europe’S First Validated Test Method to Evaluate Filtration Capacity of Masks for Sars-Cov-2

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento